Hubungan antara Kadar Prostate Specific Antigen Serum dan Skor Gleason pada Adenokarsinoma Prostat

Authors

  • Claudia Clary Navisa Fakultas Kedokteran Universitas Airlangga, Jl. Mayjen Prof. Dr. Moestopo No.47, Surabaya Jawa Timur
  • Willy Sandhika Departemen Patologi Anatomi Fakultas Kedokteran Universitas Airlangga, Jl. Mayjen Prof. Dr. Moestopo No.47, Surabaya Jawa Timur
  • Heny Arwati Departemen Parasitologi Fakultas Kedokteran Universitas Airlangga, Jl. Mayjen Prof. Dr. Moestopo No.47, Surabaya Jawa Timur

DOI:

https://doi.org/10.21776/ub.jkb.2019.030.03.3

Keywords:

Kanker prostat, prostat, prostate specific antigen, skor Gleason

Abstract

Kanker prostat adalah kanker terbanyak ke empat di dunia dan merupakan kanker terbanyak ke dua yang menyerang pria. Pada tahun 2013, angka kejadian kanker prostat di Indonesia adalah 25.012 dengan jumlah kasus terbesar yaitu di Jawa Timur sebanyak 5.668. Prostate Specific Antigen (PSA) sebagai penanda tumor, dikatakan berhubungan secara linier dengan skor Gleason. Tujuan dari penelitian ini adalah untuk mengetahui hubungan antara kadar PSA serum dengan skor Gleason pada pasien kanker prostat di RSUD Dr. Soetomo. Penelitian ini merupakan studi analitik dengan desain belah lintang. Data penelitian dikumpulkan dari data rekam medis pasien kanker prostat yang menjalani pemeriksaan kadar PSA serum dan histopatologi jaringan prostat di RSUD Dr. Soetomo Surabaya pada tahun 2015-2017. Pasien dengan Benign Prostate Hyperplasia, infeksi saluran kencing, dan prostatitis dalam 1 bulan terakhir dimasukkan ke dalam kriteria eksklusi. Pada penelitian ini didapatkan 62 sampel. Rentang usia sampel 28-85 tahun dengan proporsi terbanyak pada kelompok usia 58-72 tahun, yaitu sebesar 66,7%. Dari keseluruhan sampel, 41,3% memiliki nilai kadar PSA serum >99ng/dL dan 85,5% memiliki skor Gleason yang buruk. Hasil uji Spearman menunjukkan adanya hubungan yang bermakna (r=0,216; p=0,046) antara kadar PSA serum dan skor Gleason pada pasien kanker prostat di RSUD Dr. Soetomo Surabaya. 

Downloads

Download data is not yet available.

References

World Health Organization. Cancer. (Online) 12 September 2018. http://www.who.int/news-room/fact-sheets/detail/cancer/ [diakses tanggal 27 Oktober 2018].

American Cancer Society. Key Statistics for Prostate Cancer. (Online) 2018. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html/. [diakses tanggal 27 Oktober 2018].

Siegel RL, Miller KD, and Jemal A. Cancer statistics, 2015. 2015; 65(1): 5-29.

Badan Penelitian dan Pengembangan Kesehatan Republik Indonesia. Riset Kesehatan Dasar 2013. Jakarta: Litbangkes Kemenkes RI; 2013.

Duffy MJ. Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancer. Medical Principles and Practice. 2013; 22(1): 4-11.

Faison dan Soediarto D. Akurasi Triple Diagnostik yang Dimodifikasi (TDM) pada Tumor Padat Payudara. Majalah Kedokteran Unibraw. 2003; 19(1): 23-26.

Rodríguez JZ and O'Kennedy R. New Approaches for The Development of Diagnostic Systems for Prostate Cancer. Asian Hospital and Healthcare Management. 2017; 36: 18-23.

Sturgeon CM, Duffy MJ, Stenman U, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. Clinical Chemistry. 2008; 54(12): e11-e79.

Baydar DE dan Epstein JI. Gleason Grading System, Modification and Additions to the Original Scheme. Turkish Journal of Pathology. 2009; 25(3): 59-70.

Jayapradeep DP, VB Prakash, Philose TR, and Pai MR. Histomorphologic Correlation of PSA Levels in Prostatic Pathology. National Journal of Laboratory Medicine. 2017; 6(4): 28-32.

Ang M, Rajcic B, Foreman D, Moretti K, and O'Callaghan ME. Men Presenting with Prostate-Specific Antigen (PSA) Values of Over 100 ng/mL. British Journal of Urology International. 2016; 117(4): 68-75.

Khant VS, Goswami H, and Shah PY. Correlation of Serum Prostate-Specific Antigen Level in Various Prostate Pathology in Elderly Men. International Journal of Medical Sciencs and Public Health. 2017; 6(2): 257-261.

Singh Y, Sharma U, Tiwari P, and Saxena A. Serum PSA and Immunohistochemical Expression of p53 In Prostatic Specimens. Journal of Dental and Medical Sciences. 2017; 16(2): 41-45.

Asafudullah SM, Salam MA, and Badruddaza SM. Evaluation of Diagnostic Accuracy of Different Biomarkers for Prostate Cancer. Pakistan Journal of Medical Science. 2011; 27(1): 48-51.

Stephan C, Ralla B, and Jung K. Prostate-Spesific Antigen and Other Serum and Urine Markers in Prostate Cancer. Biochimica et Biophysica Acta. 2014; 1846(1): 99-112.

Velcheti V, Karnik S, Bardot SF, and Prakash O. Pathogenesis of Prostate Cancer: Lesson from Basic Research. The Ochsner Journal. 2008; 8(4): 213-218.

Zivkovic S. Correlation between Prostate-Specific Antigen and Histopathological Difference of Prostate Carcinoma. Archive on Oncology. 2004; 12(3): 148-151.

Mustafa M, Salih AF, Illzam EM, Sharifa AM, Suleiman M, and Hussain SS. Prostate Cancer: Pathophysiology, Diagnosis, and Prognosis. Journal of Dental and Medical Sciences. 2016; 15(6): 4-11.

Sanjaya IP, Mochtar CA, and Umbas R. Correlation between Low Gleason Score and Prostate Specific Antigen Levels with Incidence of Bone Metastases in Prostate Cancer Patients: When to Omit Bone Scans? Asian Pacific Journal of Cancer Prevention. 2013; 14(9): 4973-4976.

Gurumurthy D, Maggad R, and Patel S. Prostate Carcinoma: Correlation of Histopathology with Serum Prostate Specific Antigen. Science Journal of Clinical Medicine. 2015; 4(4): 1-5.

Downloads

Published

2019-02-28

Issue

Vol. 30 No. 3 (2019)

Section

Research Article

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).